| Item Type | Name |
|
Concept
|
Graft vs Host Disease
|
|
Academic Article
|
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
|
|
Academic Article
|
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
|
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation.
|
|
Academic Article
|
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
|
|
Academic Article
|
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
|
Academic Article
|
Chimerism does not predict for outcome after alemtuzumab based conditioning.
|
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity.
|
|
Academic Article
|
Severe intestinal graft-versus-host disease following autologous stem cell transplantation.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
|
|
Academic Article
|
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
|
|
Academic Article
|
Microchimerism and allogeneic transplantation: we need the proof in the pudding.
|
|
Academic Article
|
Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned.
|
|
Academic Article
|
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
|
|
Academic Article
|
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.
|
|
Academic Article
|
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
|
Academic Article
|
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
|
|
Academic Article
|
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
|
|
Academic Article
|
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
|
|
Academic Article
|
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
|
|
Academic Article
|
Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.
|
|
Academic Article
|
Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?
|
|
Academic Article
|
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.
|
|
Academic Article
|
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.
|
|
Academic Article
|
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
|
|
Academic Article
|
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
|
|
Academic Article
|
Allogeneic blood stem cell transplantation in advanced hematologic cancers.
|
|
Academic Article
|
Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence.
|
|
Academic Article
|
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.
|
|
Academic Article
|
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
|
|
Academic Article
|
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.
|
|
Academic Article
|
Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.
|
|
Academic Article
|
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
|
|
Academic Article
|
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
|
|
Academic Article
|
Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy.
|
|
Academic Article
|
The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
|
|
Academic Article
|
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
|
|
Academic Article
|
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
|
|
Academic Article
|
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
cGVHD of skin: simple tools, great advances.
|
|
Academic Article
|
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.
|
|
Academic Article
|
Alemtuzumab in allogeneic hematopoetic stem cell transplantation.
|
|
Academic Article
|
Stem-cell transplantation for sickle cell disease.
|
|
Academic Article
|
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
|
|
Academic Article
|
Standardizing chronic graft-versus-host disease.
|
|
Academic Article
|
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
|
|
Academic Article
|
Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.
|
|
Academic Article
|
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
|
|
Academic Article
|
Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.
|
|
Academic Article
|
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
|
|
Academic Article
|
Haplo-cord transplant: HLA-matching determines graft dominance.
|
|
Academic Article
|
Haploidentical cord transplantation-The best of both worlds.
|
|
Academic Article
|
Cord blood chimerism and relapse after haplo-cord transplantation.
|
|
Academic Article
|
Against the odds: haplo-cord grafts protect from GvHD and relapse.
|
|
Academic Article
|
Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors.
|
|
Academic Article
|
Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients.
|
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
|
Academic Article
|
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
|
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
|
Academic Article
|
Tocilizumab, in search for a role in acute GVHD.
|
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies.
|
|
Academic Article
|
Cord blood transplants supported by unrelated donor CD34+ progenitor cells.
|
|
Academic Article
|
Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match!
|
|
Academic Article
|
Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.
|
|
Grant
|
Busulfan conditioning: optimization, kinetics, genomics
|
|
Grant
|
Minor Histocompatilibity Vaccination After Allo-Transpl*
|
|
Academic Article
|
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD).
|